Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

three milestones in Roche collaboration

Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8

through asset exchange with Medarex

Commenced seven new studies:

HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA

and Phase II non small cell lung cancer study

HuMax-CD20 - Phase II front line CHOP combination study in follicular

non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed

diffuse large B-cell lymphoma study

HuMax-CD38 Phase I/II multiple myeloma study

Achieved positive clinical trial results:

HuMax-CD20 Phase II RA data

Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data

R1507 Phase I sarcoma data

Presented pre-clinical data:

Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20

Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr

Financial Highlights:

Cash position increased for fourth consecutive year

Achieved membership in OMXC20 index on the OMX Nordic Exchange

Copenhagen

2008 Guidance

We expect to significantly expand development in 2008 in our clinical and pre-clinical programs, including plans to initiate 17 new clinical studies, filing our first biologics license application and selecting two new clinical candidates. We will pay development costs for the new and ongoing pivotal studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will fund half the development costs for the trials with HuMax-CD20. We expect to continue our increasing level of discovery and pre-clinical work in 2008, developing antibody products for a variety of new and existing disease targets. Finally, the 2008 projections include operating costs from the newly acquired antibody manufacturing facility.

Due to these expanded activities, Genmab's operating costs are expected to be higher in 2008 than in 2007. In combination with increasing re
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... Earle Martin , Chief Executive ... Ellen Teplitzky, an experienced attorney specializing in business ... has joined the firm as Director of Legal ... NDA Partners provides legal services, including research, ... top law firms and their clients in cases ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Contributed by James V. Anderson and Charles L. Guy, The,University of Florida, Institute ... Introduction , ... , Glucose Regulated Proteins) are ER-luminal proteins ... 1 BiPs are associated with the transport and folding process , ...
... Contributed by Alan T. Bakalinsky Department of Food Science and Technology, ... , Abstract , ... cerevisiae were , compared to those of ... supported previous genetic findings that two of the wine strains are aneuploid , ...
... Marie Nguyen and William Strong, Bio-Rad Laboratories, Inc.,6000 James ... , Introduction , ... is an established technique employed for protein separation. However, ... manual steps and several , hours to ...
Cached Biology Technology:A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF 2A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF 3A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF 4A Rapid Method for the Purification of Analytical Grade Proteins From Plants Using Preparative SDS-PAGE and Preparative IEF 5Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 2Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 3Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 4Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 5Electrophoretic Karyotypes of Wine Strains of Saccharomyces cerevisiae 6Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 2Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 3Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 4Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 5Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 6Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 7Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 8Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 9Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 10Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 11Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 12Performance Comparison of the Experion Automated Electrophoresis System and a Competing Automated System for Protein Analysis, Rev A 13
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... (February 28, 2012) Abstracts are now being accepted ... Infectious Diseases Society of America (IDSA), the Society for ... (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). ... 17-21, 2012, in San Diego, CA. With the theme ...
... a world-leading provider of scientific, technical and medical ... scientist, Professor Dr. Manfred T. Reetz (Emeritus) of ... Professor at Philipps-Universitt, Marburg, has been awarded the ... Organic Chemistry. The Executive Board of ...
... from The University of Nottingham have demonstrated how a ... potentially immortal. The discovery, published in the ... part of a project funded by the Biotechnology and ... (MRC) and may shed light on the possibilities of ...
Cached Biology News:Leading German Researcher awarded Elsevier's 2011 Tetrahedron Prize 2Immortal worms defy aging 2Immortal worms defy aging 3
... preparations are prepared from customers high-copy ... to multi-gram scales. Each preparation is ... glycerol stocks are maintained to facilitate ... (Clonal selection includes screening colonies for ...
... channels for automated gigaseal patch clamping. ... voltage-gated ion channels, such as hERG and ... The four pipette heads afford more efficient ... drug discovery. The glass-coated tunnels of ...
... be able to handle larger sample volumes, automate ... as interface with telemetry systems. The AccuSampler ... dogs, pigs, and primates. The system may ... the computer can be located outside the animal ...
... The GST•Tag™ Antibody Plate is ... GST•Tag Monoclonal Antibody. This antibody (mouse ... S. japonicum glutathione-S-transferase (GST), ... virtually any GST•Tag fusion protein in ...
Biology Products: